Yahalom, Gilad MD∗,†,§; Atlan, Eden§; Janah, Amir MD†,§; Dominko, Melania MD†,§; Israel, Ilana BSN, MA∗; Rajz, Gustavo MD‡,§; Mausbach, Stefan MD†,§; Eichel, Roni MD†,§
∗Movement Disorders Unit
†Department of Neurology
‡Department of Neurosurgery, Shaare Zedek Medical Center
§The Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
G.Y. and E.A. contributed equally to the article.
Address correspondence and reprint requests to Corresponding author: Gilad Yahalom, Movement Disorders Unit, Department of Neurology, Shaare Zedek Medical Center, Jerusalem, Israel; E-mail: [email protected]
Conflict of interests and source of funding: G.Y. received consultation fee from Allergan. The other authors have no conflicts of interest to declare.
Clinical Neuropharmacology ():10.1097/WNF.0000000000000548, March 13, 2023. | DOI: 10.1097/WNF.0000000000000548